Publications

Selected Publications

Wang J, Okkeri J, Pavic K, Wang Z, Kauko O, Halonen T, Sarek G, Ojala PM, Rao Z, Xu W, Westermarck J; Oncoprotein CIP2A is stabilized via interaction with tumor suppressor PP2A/B56. EMBO Rep. 2017 Mar;18(3):437-450

Kaur A, Denisova O, Qiao X, Jumppanen M, Peuhu E, Ahmed SU, Raheem O, Haapasalo HK, Eriksson J, Chalmers AJ, Laakkonen PM, Westermarck J; PP2A inhibitor PME-1 drives kinase inhibitor resistance in glioma cells. Cancer Res. 2016 Sep 26

Pokharel YR, Saarela J, Szwajda A, Rupp C, Rokka A, Karna SKL, Teittinen K, Corthals G, Kallioniemi O, Wennerberg K, Aittokallio T and Westermarck J; Relevance Rank Platform (RRP) for functional filtering of high content protein-protein interaction data. Mol Cell Proteomics, 2015 Dec;14(12):3274-83.

Ventelä S, Sittig E, Mannermaa L, Mäkelä J-A, Kulmala J, Löyttyniemi E, Strauss L, Cárpen O, Toppari J, Grénman R and Westermarck J; CIP2A is an Oct4 target gene involved in head and neck squamous cell cancer oncogenicity and radioresistance. Oncotarget 6(1): 144-158, 2015.

Kauko O, Laajala TD, Jumppanen M, Hintsanen P, Suni V, Haapaniemi P, Corthals G, Aittokallio T, Westermarck J & Imanishi SY, Label-free quantitative phosphoproteomics with novel pairwise abundance normalization reveals synergistic RAS and CIP2A signalling. Sci Rep. 2015 Aug 17;5:13099

Myant K, Qiao X, Halonen T, Come C, Laine A, Janghorban M, Partanen JI, Cassidy J, Ogg EL, Cammareri P, Laiterä T, Okkeri J, Klefström J, Sears RC, Sansom OJ, Westermarck J. Serine 62-Phosphorylated MYC Associates with Nuclear Lamins and Its Regulation by CIP2A Is Essential for Regenerative Proliferation. Cell Rep. 2015 Jul 28

Khanna A, Kauko O, Bockelman C, Laine A, Schreck I, Partanen JI, Szwajda A, Bormann S, Bilgen T, Helenius M, Pokharel YR, Pimanda J, Russel MR, Haglund C, Cole KA, Klefstrom J, Aittokallio T, Weiss C, Ristimaki A, Visakorpi T, Westermarck J. Chk1 targeting reactivates PP2A tumor suppressor activity in cancer cells. Cancer Res. 2013 Nov 15;73(22):6757-69

Laine A, Sihto H, Come C, Rosenfeldt MT, Zwolinska A, Niemelä M, Khanna A, Chan EK, Kähäri VM, Kellokumpu-Lehtinen PL, Sansom OJ, Evan GI, Junttila MR, Ryan KM, Marine JC, Joensuu H, Westermarck J. Senescence sensitivity of breast cancer cells is defined by positive feedback loop between CIP2A and E2F1. Cancer Discov. 2013 Jan 10;3(2):182-97

Ventelä S, Mäkelä J-A, Kulmala J, Westermarck J, and Toppari J: Identification and regulation of a stage-specific stem cell niche enriched by Nanog positive spermatogonial stem cells in the mouse testis. STEM CELLS,2012 May;30(5):1008-20. 

Ventelä, S., Come, C., Mäkelä, J.-A., Hobbs, R.M., Mannermaa, L., Kallajoki, M., Chan, E.K., Pandolfi, P.P., Toppari, J. and Westermarck, J: CIP2A promotes proliferation of spermatogonial progenitor cells and spermatogenesis in mice.  Plos ONE, 2012;7(3).

Niemelä M, Kauko O, Sihto H, Mpindi J-P, Nicorici D, Pernilä P, Kallioniemi O-P, Joensuu H, Hautaniemi S, and Westermarck J: CIP2A signature reveals the MYC dependency of CIP2A-regulated phenotypes and its clinical association with breast cancer subtypes. Oncogene, 2012; Sep 27;31(39):4266-78. 

Come C, Laine A, Chanrion M, Edgren H, Mattila E, Liu X, Jonkers J, Ivaska J, Isola J, Darbon J-M, Kallioniemi O-P, and Thezenas S and Westermarck J; CIP2A is associated with human breast cancer aggressivity. Clinical Cancer Research, 15, 5092-5100, 2009.

Khanna A, Böckelman C, Hemmes A, Junttila MR, Wiksten J-P, Lundin P, Junnila S, Murphy D, Evan GI, Haglund C, Westermarck J*, and Ristimäki A*; c-Myc-dependent regulation and prognostic role of CIP2A in gastric cancer. Journal of the National Cancer Institute, 101, 793-805, 2009. *equal contribution

Puustinen P, Junttila MR, Vanhatupa S, Sablina AA, Hector ME, Teittinen K, Raheem O, Ketola K, Lin S, Kast J, Haapasalo H, Hahn WC, and Westermarck J; PME-1 Protects ERK Pathway activity from Protein Phosphatase 2A-mediated Inactivation in human malignant glioma. Cancer Research, 69, 2870-2877, 2009.

Wu J, Ovaska K, Vallenius T, Westermarck J, Mäkelä TP, and Hautaniemi S; Protein-protein interaction portal for network level analysis. Nature Methods, 6, 75-77, 2009

Junttila, MR, Puustinen P, Niemelä M, Ahola R, Arnold H, Böttzauw T, Ala-aho R, Nielsen C, Ivaska J, Taya Y, Lu SL, Li S, Chan EKL, Wang X-J, Grenman R, Kast J, Kallunki T, Sears R, Kähäri V-M, Westermarck J; CIP2A Inhibits PP2A in Human Malignancies. Cell, 130, 51–62, 2007.

Reviews

Laine A, Westermarck J. Molecular pathways: harnessing E2F1 regulation for prosenescence therapy in p53-defective cancer cells. Clin Cancer Res. 2014 Jul 15;20(14):3644-50.

Khanna A, Pimanda JE, Westermarck J. Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A), an emerging human oncoprotein and a potential cancer therapy target. Cancer Res. 2013 Nov 15;73(22):6548-53

Westermarck J; Regulation of transcription factor function by targeted protein degradation: an overview focusing on p53, c-Myc, and c-Jun. Methods Mol Biol., 647, 31-36, 2010.

Westermarck J, Hahn WC; Multiple pathways regulated by the tumor suppressor PP2A in transformation. Trends in Molecular Medicine, 14,152-160, 2008.

Junttila MR, Li S-P, Westermarck J; Phosphatase-mediated cross-talk between MAPK signaling pathways in the regulation of cell survival. The FASEB Journal, 22, 954-965, 2008.